Mine Safety and Health Research Advisory Committee (MSHRAC), 25451-25452 [2020-09306]
Download as PDF
<![CDATA[
Federal Register / Vol. 85, No. 85 / Friday, May 1, 2020 / Notices
C. NIOSH List of Hazardous Drugs in
Healthcare Settings, 2020—Title,
Reorganization, and Removals
NIOSH has retitled and reorganized
the List in response to comments
received. Many of the drugs currently
used to fight cancer function differently
than those previously used.
Antineoplastic drugs are no longer all
cytotoxic, genotoxic, and highly
hazardous chemicals. Therefore, when
drugs are grouped by their function (i.e.,
antineoplastic), as they were in earlier
versions of Table 1, drugs that required
different protective measures were
grouped together (non-cytotoxic drugs
with cytotoxic drugs). NIOSH has
determined that grouping all
antineoplastic drugs together in one
table is no longer the most useful or
informative for users. Therefore, NIOSH
has regrouped the tables by hazard. The
List now comprises only two tables:
Table 1: Drugs that contain MSHI in the
package insert and/or meet the NIOSH
definition of a hazardous drug and are
classified by NTP as ‘‘known to be a human
carcinogen,’’ or classified by IARC as
‘‘carcinogenic’’ or ‘‘probably carcinogenic.’’
Table 2: Drugs that meet the NIOSH
definition of a hazardous drug, but do not
have MSHI and are not classified by NTP as
‘‘known to be a human carcinogen,’’ or
classified by IARC as ‘‘carcinogenic’’ or
‘‘probably carcinogenic.’’
Additional changes to the List,
including those drugs proposed for
removal from the List, are described in
detail in the draft NIOSH List of
Hazardous Drugs in Healthcare Settings,
2020, which is available for review in
the docket for this activity.
IV. Risk Management for Hazardous
Drugs in Healthcare Settings
In the 2016 List, Table 5 provided
information on recommended exposure
controls for hazardous drugs based on
formulations. In order to clarify that the
List is a hazard identification tool,
NIOSH has removed this table from the
document. In its place, NIOSH has
developed a new, comprehensive
document on risk management
strategies entitled, Managing Hazardous
Drug Exposures: Information for
Healthcare Settings, which includes a
revision of this table on control
approaches to safe handling of
hazardous drugs. The new risk
management document is available for
review in the docket for this activity.
NIOSH is seeking input from the
public on the draft risk management
strategies document and table to ensure
that they contain accurate and helpful
information. Independent peer
reviewers are being consulted as well;
their charge is available on the NIOSH
VerDate Sep<11>2014
08:07 May 01, 2020
Jkt 250001
website 9 and includes the following
questions. NIOSH encourages public
comment on these questions.
1. Please provide feedback on the
overall document:
a. What additional information would
improve its usefulness and why?
b. What changes could be made to
improve the utility of the information?
c. What information is redundant,
incorrect, missing, or not needed?
Please explain.
2. Please provide any additional
studies or scientific information that
evaluate or validate engineering, work
practice or administrative controls to
reduce exposures to hazardous drugs in
healthcare settings.
3. Please provide any additional
studies or scientific information that
support or validate the use of the
NIOSH recommended control strategies
or alternative strategies to control
exposures to hazardous drugs.
4. Please provide any additional
studies or scientific information that
support or validate evidence-based
strategies or approaches for controlling
exposures to hazardous drugs that are
different from those that NIOSH has
proposed.
5. NIOSH has provided its proposed
recommendations and related
information about controlling hazardous
drugs in the Table of Control
Approaches in Chapter 8.
a. What additional information would
improve the usefulness of this table and
why?
b. What structural or format changes
could be made to improve the utility of
this table?
c. What information is redundant,
incorrect, missing, or not needed?
Please explain.
6. What improvements could be made
to this risk management information to
make it more useful to employers and
healthcare workers? Please provide
specific examples.
7. Please provide information about
your professional experience, if any, of
implementing control strategies for
exposures to hazardous drugs in
healthcare or similar settings. Please
describe what you found to be most or
least effective and why. Include relevant
publications if available.
8. Please provide any additional
studies or scientific information related
to the use of a medical surveillance
program as an additional approach to
protect workers in healthcare settings.
Information of particular interest
includes considerations for design and
9 NIOSH Peer Review Agenda, https://
www.cdc.gov/niosh/review/peer/isi/
healthsafetyrisks.html.
PO 00000
Frm 00069
Fmt 4703
Sfmt 4703
25451
implementation of a medical
surveillance program, data analysis, and
communication of results to
participants.
John J. Howard,
Director,National Institute for Occupational
Safety and Health, Centers for Disease Control
and Prevention.
[FR Doc. 2020–09332 Filed 4–30–20; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Mine Safety and Health Research
Advisory Committee (MSHRAC)
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of meeting.
AGENCY:
In accordance with the
Federal Advisory Committee Act, the
CDC announces the following meeting
for the Mine Safety and Health Research
Advisory Committee (MSHRAC). This is
a virtual meeting. It is open to the
public, limited only by web conference
lines (500 web conference lines are
available). If you wish to attend, please
contact Marie Chovanec by email at
MChovanec@cdc.gov or by telephone at
412–386–5302 at least 5 business days
in advance of the meeting. She will
provide you the Zoom web conference
access.
DATES: The meeting will be held on June
2, 2020, 10:00 a.m.–2:30 p.m., EDT.
ADDRESSES: The Zoom web conference
access can be obtained via email at
MChovanec@cdc.gov or by telephone at
412–386–5302.
FOR FURTHER INFORMATION CONTACT:
Jeffrey H. Welsh, Designated Federal
Officer, MSHRAC, NIOSH, CDC, 626
Cochrans Mill Road, Pittsburgh, PA
15236, telephone 412–386–4040; email
jwelsh@cdc.gov.
SUPPLEMENTARY INFORMATION:
Purpose: This committee is charged
with providing advice to the Secretary,
Department of Health and Human
Services; the Director, CDC; and the
Director, NIOSH, on priorities in mine
safety and health research, including
grants and contracts for such research,
30 U.S.C. 812(b)(2), Section 102(b)(2).
Matters to be Considered: The agenda
will include discussions on mining
safety and health research projects and
outcomes, including updates from one
MSHRAC Workgroup, the Health
Advisory in the Mining Program
SUMMARY:
E:\FR\FM\01MYN1.SGM
01MYN1
25452
Federal Register / Vol. 85, No. 85 / Friday, May 1, 2020 / Notices
(HAMP) Workgroup, NIOSH Miner
Health Program strategic plan, NIOSH
Mining respirable crystalline silica
research, Understanding elongate
mineral particle exposure in mining,
Research roadmap for haul truck health
and safety issues, and Future of the coal
industry presentation. The meeting will
also include an update from the NIOSH
Associate Director for Mining. Agenda
items are subject to change as priorities
dictate.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2020–09306 Filed 4–30–20; 8:45 am]
BILLING CODE 4163–18–P
Centers for Disease Control and
Prevention
Advisory Committee on Breast Cancer
in Young Women (ACBCYW);
Cancellation of Meeting
Notice is hereby given of a change in
the meeting of the Advisory Committee
on Breast Cancer in Young Women
(ACBCYW); May 13, 2020, 8:00 a.m. to
1:00 p.m., EDT.
The teleconference and web
conference, which was published in the
Federal Register on March 16, 2020,
Volume 85, Number 51, page 14945, is
being canceled in its entirety.
FOR FURTHER INFORMATION CONTACT:
Jeremy McCallister, Designated Federal
Officer, National Center for Chronic
Disease Prevention and Health
Promotion, CDC, 4770 Buford Hwy. NE,
Mailstop S107–4, Atlanta, Georgia
30341, Telephone (404) 639–7989, Fax
(770) 488–4760; Email: acbcyw@
cdc.gov.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
08:07 May 01, 2020
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2020–09305 Filed 4–30–20; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket No. CDC–2019–0069]
Proposed Update of the CDC’s 2006
Revised Recommendations for HIV
Testing of Adults, Adolescents, and
Pregnant Women in Health-Care
Settings; Re-opening of the Comment
Period
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice.
AGENCY:
The Centers for Disease
Control and Prevention (CDC) in the
Department of Health and Human
Services (HHS) announces the reopening of this docket to obtain
additional public comment on the
proposed update of the 2006 Revised
Recommendations for HIV Testing. CDC
is re-opening this docket at the request
of the public.
DATES: Electronic or written comments
must be received by June 30, 2020.
ADDRESSES: You may submit comments,
identified by Docket No. CDC–2019–
0069, by any of the following methods
below. CDC does not accept public
comment by email.
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: DHAP Guideline Team,
Centers for Disease Control and
Prevention, 1600 Clifton Road, NE, MS
US8–4, Atlanta, Georgia 30329.
FOR FURTHER INFORMATION CONTACT:
Priya Jakhmola, Health Scientist,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE, MS
US8–4, Atlanta, Georgia 30329.
Telephone: 404–639–2495, Email:
dhapguideline@cdc.gov.
SUPPLEMENTARY INFORMATION:
SUMMARY:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
VerDate Sep<11>2014
Prevention and the Agency for Toxic
Substances and Disease Registry.
Jkt 250001
Public Participation
Interested persons or organizations
are invited to participate by submitting
written views, recommendations, and
data related to HIV screening
approaches. In addition, CDC invites
PO 00000
Frm 00070
Fmt 4703
Sfmt 4703
comments specifically on opt-out
routine HIV testing, including, but not
limited to:
• Suggestions for revisions, edits, and
new additions
• Contemporary issues and new
evidence
• Implementation barriers, challenges,
and lessons learned
• Examples of innovative models,
partnerships, and collaborations
Please note that comments received,
including attachments and other
supporting materials, are part of the
public record and are subject to public
disclosure. Comments will be posted on
https://www.regulations.gov. Therefore,
do not include any information in your
comments or supporting materials that
you consider confidential or
inappropriate for public disclosure. If
you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be on
public display. CDC will review all
submissions and may choose to redact,
or withhold, submissions containing
private or proprietary information,
inappropriate language, or examples of
a mass-mail campaign. CDC will
carefully consider all comments
submitted in preparation of the final
document and may revise the final
document as appropriate.
Background
On August 30, 2019, CDC published
a notice (84 FR 45495) announcing the
availability of a Proposed Update of the
CDC’s 2006 Revised Recommendations
for HIV Testing of Adults, Adolescents,
and Pregnant Women in Health-Care
Settings. The comment period ended
October 28, 2019. CDC received a
request from the public to re-open the
comment period.
The CDC guideline ‘‘Revised
Recommendations for HIV Testing of
Adults, Adolescents, and Pregnant
Women in Health-Care Settings’’ was
published on September 22, 2006 in
CDC’s Morbidity and Mortality Weekly
Report (MMWR). Since then, there have
been changes in evidence related to HIV
testing technologies and interventions,
disease epidemiology, outcomes,
implementation resources, and related
guidelines. This evidence will be
identified, assessed, and analyzed to
inform the update of the guideline.
CDC will update the 2006 guideline
based on input from subject matter
experts, public health agencies, the
public, and other stakeholders. The
guideline development process will
draw on up-to-date nationally and
internationally accepted guideline
E:\FR\FM\01MYN1.SGM
01MYN1
]]>Agencies
[Federal Register Volume 85, Number 85 (Friday, May 1, 2020)]
[Notices]
[Pages 25451-25452]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-09306]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Mine Safety and Health Research Advisory Committee (MSHRAC)
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice of meeting.
-----------------------------------------------------------------------
SUMMARY: In accordance with the Federal Advisory Committee Act, the CDC
announces the following meeting for the Mine Safety and Health Research
Advisory Committee (MSHRAC). This is a virtual meeting. It is open to
the public, limited only by web conference lines (500 web conference
lines are available). If you wish to attend, please contact Marie
Chovanec by email at [email protected] or by telephone at 412-386-5302
at least 5 business days in advance of the meeting. She will provide
you the Zoom web conference access.
DATES: The meeting will be held on June 2, 2020, 10:00 a.m.-2:30 p.m.,
EDT.
ADDRESSES: The Zoom web conference access can be obtained via email at
[email protected] or by telephone at 412-386-5302.
FOR FURTHER INFORMATION CONTACT: Jeffrey H. Welsh, Designated Federal
Officer, MSHRAC, NIOSH, CDC, 626 Cochrans Mill Road, Pittsburgh, PA
15236, telephone 412-386-4040; email [email protected].
SUPPLEMENTARY INFORMATION:
Purpose: This committee is charged with providing advice to the
Secretary, Department of Health and Human Services; the Director, CDC;
and the Director, NIOSH, on priorities in mine safety and health
research, including grants and contracts for such research, 30 U.S.C.
812(b)(2), Section 102(b)(2).
Matters to be Considered: The agenda will include discussions on
mining safety and health research projects and outcomes, including
updates from one MSHRAC Workgroup, the Health Advisory in the Mining
Program
[[Page 25452]]
(HAMP) Workgroup, NIOSH Miner Health Program strategic plan, NIOSH
Mining respirable crystalline silica research, Understanding elongate
mineral particle exposure in mining, Research roadmap for haul truck
health and safety issues, and Future of the coal industry presentation.
The meeting will also include an update from the NIOSH Associate
Director for Mining. Agenda items are subject to change as priorities
dictate.
The Director, Strategic Business Initiatives Unit, Office of the
Chief Operating Officer, Centers for Disease Control and Prevention,
has been delegated the authority to sign Federal Register notices
pertaining to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention and
the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2020-09306 Filed 4-30-20; 8:45 am]
BILLING CODE 4163-18-P
